FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APP	ROVAL
OMB Number:	3235-0287
Estimated average b	ourden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Curran Terrie					2. Issuer Name and Ticker or Trading Symbol Arcutis Biotherapeutics, Inc. [ARQT]							(Ch	eck all applic	or	Perso	10% Ow	ner	
(Last) (First) (Middle) C/O ARCUTIS BIOTHERAPEUTICS, INC.					3. Date of Earliest Transaction (Month/Day/Year) 11/02/2020									Officer (give title below)		Other (s	pecify	
2945 TOWNSGATE ROAD SUITE 110				-	A KANANANA BARAKSA KANANA BARAKSA KANANA							0.1	6 Individual or Jaint/Croup Filing (Cheek Anglianh)					
(Street) WESTLA	C	² CA 91361				4. If Amendment, Date of Original Filed (Month/Day/Year)							ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)															
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				Execution Date,		Code (Instr. 5)			tr. 3, 4 and	Beneficia Owned F Reported	es Forn ally (D) o Following (I) (Ir		n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
								Code	′	Amount	(A) or (D)	Price	Transact (Instr. 3					
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amou of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	y	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)		
		Code V (A) (D) Exercisable Expiration Date Expiration Date Title Shares																
Stock Option (Right to Buy)	\$18.72	11/02/2020		A		37,500		(1)	11	/02/2030	Common Stock	37,500	\$0.00	37,500		D		

Explanation of Responses:

1. The option vests as to 1/3 of the total shares on each of November 2, 2021, November 2, 2022 and November 2, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

/s/ John W. Smither, as

Attorney-in-Fact for Terrie

11/04/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.